Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2. J of Skin 2025, 9 (6), s662. https://doi.org/10.25251/t6v95c18.